CD52, CD22, CD26, EG5 and IGF-1R expression in thymic malignancies

Highlights • Immunohistochemistry is a valid tool to identify overexpression of predictive markers • EG5 expression was significantly higher in thymic carcinomas • Agents targeting CD52, CD 22, CD26 and EG5 could be further explored in TET patients

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Lung cancer (Amsterdam, Netherlands) Netherlands), 2017-06, Vol.108, p.168-172
Hauptverfasser:	Remon, J., M.D, Abedallaa, N., M.D, Taranchon-Clermont, E, Bluthgen, V., M.D, Lindsay, C.R., M.D, Ph. D, Besse, B., M.D, Ph.D, Thomas de Montpréville, V
Format:	Artikel
Sprache:	eng
Schlagworte:	Biomarkers Biomarkers, Tumor CD22 CD26 CD52 CD52 Antigen - genetics CD52 Antigen - metabolism Dipeptidyl Peptidase 4 - genetics Dipeptidyl Peptidase 4 - metabolism EG5 Female Gene Expression Hematology, Oncology and Palliative Medicine Humans IGF-1R Immunohistochemistry Kinesin - genetics Kinesin - metabolism Male Prognosis Protein Transport Pulmonary/Respiratory Receptors, Somatomedin - genetics Receptors, Somatomedin - metabolism Sialic Acid Binding Ig-like Lectin 2 - genetics Sialic Acid Binding Ig-like Lectin 2 - metabolism Thymic Thymus Neoplasms - genetics Thymus Neoplasms - metabolism Thymus Neoplasms - mortality Thymus Neoplasms - pathology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Highlights • Immunohistochemistry is a valid tool to identify overexpression of predictive markers • EG5 expression was significantly higher in thymic carcinomas • Agents targeting CD52, CD 22, CD26 and EG5 could be further explored in TET patients
ISSN:	0169-5002 1872-8332
DOI:	10.1016/j.lungcan.2017.03.019